Our study identifies key clinical predictors—post-menopausal status, Hispanic or Arabic ethnicity, and the HER2+ tumor subtype—that are associated with a shorter time to BM development, offering potential targets for early screening in high-risk patients. This evidence concerns the gene ERBB2 and neoplasm.